145 related articles for article (PubMed ID: 2882148)
1. Vasoactive intestinal peptide producing tumour contains high density of somatostatin receptors.
Reubi JC; Heitz PU; Gyr K
Lancet; 1987 Mar; 1(8535):741-2. PubMed ID: 2882148
[No Abstract] [Full Text] [Related]
2. Secretin, cholecystokinin, and vasoactive intestinal polypeptide in pancreatic cholera.
Achord JL
Ann Intern Med; 1986 Oct; 105(4):632. PubMed ID: 3019205
[No Abstract] [Full Text] [Related]
3. Mechanisms of vasoactive intestinal peptide release in short-term culture of vasoactive intestinal peptide-producing tumor.
Harty RF; Jain DK; McGuigan JE
Gastroenterology; 1988 Feb; 94(2):513-8. PubMed ID: 2446951
[TBL] [Abstract][Full Text] [Related]
4. Vasoactive intestinal peptide producing neuroblastoma.
Cooney DR; Voorhess ML; Fisher JE; Brecher M; Karp MP; Jewett TC
J Pediatr Surg; 1982 Dec; 17(6):821-25. PubMed ID: 6298396
[TBL] [Abstract][Full Text] [Related]
5. Watery diarrhea syndrome caused by multihormonal malignant pancreatic islet cell tumor secreting somatostatin, vasoactive intestinal peptide, serotonin, and prostaglandin E--a clinicopathological, biochemical, immunohistochemical, and ultrastructural study.
Chen YF; Liu TH; Chen SP; Pan GZ; Lu XH; Lu GJ; Zhong SX; Cai LX; Cui QC; Ran QY
Pancreas; 1986; 1(1):80-9. PubMed ID: 2883647
[TBL] [Abstract][Full Text] [Related]
6. Can inhibition of hormone secretion be associated with endocrine tumour shrinkage?
Kraenzlin ME; Ch'ng JC; Wood SM; Bloom SR
Lancet; 1983 Dec 24-31; 2(8365-66):1501. PubMed ID: 6140590
[No Abstract] [Full Text] [Related]
7. [Successful therapy of VIPoma with the long-acting somatostatin analogue SMS 201-995].
Maeda M; Niitsu Y; Goto Y; Kogawa K; Watanabe N; Kohgo Y; Urushizaki I
Nihon Naika Gakkai Zasshi; 1988 Jan; 77(1):86-90. PubMed ID: 2897419
[No Abstract] [Full Text] [Related]
8. Watery diarrhoea and a vasoactive intestinal peptide secreting ganglioneuroma.
Dorney SF; Kamath KR; Shulkes AA; Middleton AW
Med J Aust; 1984 Jan; 140(2):97-9. PubMed ID: 6319979
[TBL] [Abstract][Full Text] [Related]
9. Pancreatic cholera syndrome: effect of a synthetic somatostatin analog on intestinal water and ion transport.
Santangelo WC; O'Dorisio TM; Kim JG; Severino G; Krejs GJ
Ann Intern Med; 1985 Sep; 103(3):363-7. PubMed ID: 2862821
[TBL] [Abstract][Full Text] [Related]
10. Somatostatin and analogues in the treatment of VIPoma.
O'Dorisio TM; Gaginella TS; Mekhjian HS; Rao B; O'Dorisio MS
Ann N Y Acad Sci; 1988; 527():528-35. PubMed ID: 2898913
[No Abstract] [Full Text] [Related]
11. Modulation of functional gastrointestinal endocrine tumors by endogenous and exogenous somatostatin.
Ellison EC; O'Dorisio TM; Benson GD
Am J Surg; 1986 Jun; 151(6):668-75. PubMed ID: 2872829
[No Abstract] [Full Text] [Related]
12. Escape of the response to a long-acting somatostatin analogue (SMS 201-995) in patients with VIPoma.
Koelz A; Kraenzlin M; Gyr K; Meier V; Bloom SR; Heitz P; Stalder H
Gastroenterology; 1987 Feb; 92(2):527-31. PubMed ID: 2878857
[TBL] [Abstract][Full Text] [Related]
13. Expression of peptide receptors in human endocrine tumours of the pancreas.
Tang C; Biemond I; Lamers CB
Gut; 1997 Feb; 40(2):267-71. PubMed ID: 9071943
[TBL] [Abstract][Full Text] [Related]
14. VIPoma syndrome.
Krejs GJ
Am J Med; 1987 May; 82(5B):37-48. PubMed ID: 3035922
[TBL] [Abstract][Full Text] [Related]
15. Long-term treatment of a VIPoma with somatostatin analogue resulting in remission of symptoms and possible shrinkage of metastases.
Kraenzlin ME; Ch'ng JL; Wood SM; Carr DH; Bloom SR
Gastroenterology; 1985 Jan; 88(1 Pt 1):185-7. PubMed ID: 2856877
[TBL] [Abstract][Full Text] [Related]
16. A combined glucagonoma and VIPoma syndrome. First pathologic and clinical report.
Cavallo-Perin P; De Paoli M; Guiso G; Sapino A; Papotti M; Coda R; Pagano G
Cancer; 1988 Dec; 62(12):2576-9. PubMed ID: 2847862
[TBL] [Abstract][Full Text] [Related]
17. Characterization of a pancreatic tumor containing vasoactive intestinal peptide, neurotensin, and pancreatic polypeptide.
Shulkes A; Boden R; Cook I; Gallagher N; Furness JB
J Clin Endocrinol Metab; 1984 Jan; 58(1):41-8. PubMed ID: 6315763
[TBL] [Abstract][Full Text] [Related]
18. Primary endocrine-secreting pancreatic tumors.
Macaron C
Am Fam Physician; 1980 Apr; 21(4):94-8. PubMed ID: 6103668
[TBL] [Abstract][Full Text] [Related]
19. Somatostatin receptor scintigraphy: the definitive technique for characterizing vasoactive intestinal peptide-secreting tumors.
Thomason JW; Martin RS; Fincher ME
Clin Nucl Med; 2000 Sep; 25(9):661-4. PubMed ID: 10983749
[TBL] [Abstract][Full Text] [Related]
20. Location of a VIPoma by iodine-123-vasoactive intestinal peptide scintigraphy.
Virgolini I; Kurtaran A; Leimer M; Kaserer K; Peck-Radosavljevic M; Angelberger P; Hübsch P; Dvorak M; Valent P; Niederle B
J Nucl Med; 1998 Sep; 39(9):1575-9. PubMed ID: 9744346
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
